Cancer vaccines: Between the idea and the reality

被引:493
作者
Finn, OJ [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Inst Canc, Dept Immunol, Pittsburgh, PA 15261 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nri1150
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Whether vaccines are designed to prepare the immune system for the encounter with a pathogen or with cancer, certain common challenges need to be faced, such as what antigen and what adjuvant to use, what type of immune response to generate and how to make it long lasting. Cancer, additionally, presents several unique hurdles. Cancer vaccines must overcome immune suppression exerted by the tumour, by previous therapy or by the effects of advanced age of the patient. If used for cancer prevention, vaccines must elicit effective long-term memory without the potential of causing autoimmunity. This article addresses the common and the unique challenges to cancer vaccines and the progress that has been made in meeting them. Considering how refractory cancer has been to standard therapy, efforts to achieve immune control of this disease are well justified.
引用
收藏
页码:630 / 641
页数:12
相关论文
共 173 条
  • [1] A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L
    Ahlers, JD
    Belyakov, IM
    Terabe, M
    Koka, R
    Donaldson, DD
    Thomas, EK
    Berzofsky, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) : 13020 - 13025
  • [2] Immunological memory and protective immunity: Understanding their relation
    Ahmed, R
    Gray, D
    [J]. SCIENCE, 1996, 272 (5258) : 54 - 60
  • [3] Vaccinology:: past achievements, present roadblocks and future promises
    André, FE
    [J]. VACCINE, 2003, 21 (7-8) : 593 - 595
  • [4] Apostolopoulos V, 1999, CURR OPIN MOL THER, V1, P98
  • [5] Apostolopoulos V, 1997, J IMMUNOL, V159, P5211
  • [6] Banchereau J, 2001, CANCER RES, V61, P6451
  • [7] Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137)
    Bansal-Pakala, P
    Croft, M
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (09) : 5005 - 5009
  • [8] Barratt-Boyes SM, 1999, CLIN CANCER RES, V5, P1918
  • [9] Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
    Belli, F
    Testori, A
    Rivoltini, L
    Maio, M
    Andreola, G
    Sertoli, MR
    Gallino, G
    Piris, A
    Cattelan, A
    Lazzari, I
    Carrabba, M
    Scita, G
    Santantonio, C
    Pilla, L
    Tragni, G
    Lombardo, C
    Arienti, F
    Marchianò, A
    Queirolo, P
    Bertolini, F
    Cova, A
    Lamaj, E
    Ascani, L
    Camerini, R
    Corsi, M
    Cascinelli, N
    Lewis, JJ
    Srivastava, P
    Parmiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4169 - 4180
  • [10] Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases
    Berd, D
    Sato, T
    Cohn, H
    Maguire, HC
    Mastrangelo, MJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (04) : 531 - 539